The growth is mainly due to the growing number of chronic diseases and government initiatives. Next Generation Sequencing Market Size was valued at USD 4.1 billion in 2018 and is expected to witness 20.4% CAGR from 2019 to 2025.. Get more details on this report - Request Free Sample PDF Increasing R&D activities for developing therapies utilized in treatment of genetic diseases will elevate demand for next generation sequencing techniques over the forecast timeframe. Shares of Illumina dropped more than 16% in extended trading after the genetics company slashed its full-year guidance and previewed disappointing second-quarter revenue. Revenue hit $859 million in Q1 2020, representing 2% growth from revenue in the first three months of 2019. Illumina expects to report its full second-quarter results on July 29. Five years ago, the stock cost about $220 per share. Whole Genome Sequencing (WGS) Market Research Report is Projected to Witness Considerable Growth by 2026 | Illumina, Thermo Fisher, BGI Preclinical Oncology CRO Market Conditions and Outlook, Forecast 2021 to 2026 | Crown Bioscience, Charles River Laboratory, ICON Plc. Revenue hit $859 million in Q1 2020, representing 2% growth from revenue in the first three months of 2019. GRAIL extends Illumina's portfolio … ", Illumina announced in June that it had acquired Dutch cloud-based software company BlueBee to expand its data processing capacity. If you're wondering whether now is a prime opportunity to buy shares of Illumina, you're not alone.Â, Here's what you should know before purchasing this large-cap stock.Â. Meanwhile, the company’s market cap hovers around $44.7 … This isn't all that surprising. Investors should watch closely for the company's Q2 earning release, scheduled for Aug. 6. Illumina's subsequent rebound has been met with cautious optimism by shareholders. Illumina also reported weakness in the direct-to-consumer market. We want to hear from you. A sales consultant with Illumina displays a flow cell at a symposium in La Jolla, California. The market is estimated to grow with a CAGR of 21.7% from 2018-2025. Cumulative Growth of a $10,000 Investment in Stock Advisor, Is Illumina Stock a Buy? GRAIL extends Illumina’s portfolio to include cancer screening, diagnosis and cancer monitoring, creating a portfolio of best-in-class, proprietary tests in each of the major oncology testing application areas. Get this delivered to your inbox, and more info about our products and services. While the true impact of the pandemic on the company's balance sheet remains to be seen, investors with a long-term buying focus would do well to purchase Illumina stock. Illumina generated revenue of $2.75 billion last year, and the company is on track to make around $3.3 billion in 2018. Increases Illumina’s Directly Accessible Total Addressable Market and Offers Multiple Future Growth Opportunities. At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. Got a confidential news tip? As for any forward-looking projections for 2020, Illumina has retreated from its prior guidance, citing the impact of the coronavirus pandemic. Returns as of 01/24/2021. Illumina has grown from just $10 million in revenues … The company went public at $16 per share on July 28, 2000. She leverages her background and education in the legal field to inform her detailed research and analysis of the stock market. Global Business and Financial News, Stock Quotes, and Market Data and Analysis. Data is a real-time snapshot *Data is delayed at least 15 minutes. By the middle of March, the stock was down roughly 36% year to date. Increases Illumina’s Directly Accessible Total Addressable Market and Offers Multiple Future Growth Opportunities. Size and Growth of the Market . Sign up for free newsletters and get more CNBC delivered to your inbox. Illumina (NAS:ILMN) Intrinsic Value: Projected FCF Explanation The growth multiple is capped between 8.35 and 17.74. In fiscal 2019, Illumina's revenue rose by 6% on a year-over-year basis to roughly $3.5 billion. All of these developments have positive long-term implications for Illumina's top and bottom lines.Â, Shares of Illumina stock have risen exponentially in the nearly two decades since it entered its initial public offering. @themotleyfool #stocks $ILMN $PACB, 3 Unstoppable Stocks To Buy Before or After the Election, Why Illumina's Q3 Results Were Better Than They Might Seem, Illumina Inc (ILMN) Q3 2020 Earnings Call Transcript, The 1 Stock Most Likely to Win From a Potentially Game-Changing Coronavirus Discovery, Copyright, Trademark and Patent Information. Significant years in the analysis are: Historical year – 2014-2019 ; Base year – 2019; Forecast period** – 2020 to 2025 [** unless otherwise stated] Illumina said it now expects revenue to grow about 6% this fiscal year. Genomics Market Projected To Be Worth USD 47.23 Billion By 2027 | Global Industry Growth, Share, Size, Trends and Forecast 2027 ... Market Growth – CAGR of 13.1% ... Illumina… Forecasted annual earnings growth. The report also provides detail study on the trending innovations, business models, growth factors and every information about the big companies that will be present in the future market insights. The stock closed at just 0.4% below its 52-week high on Friday, July 17. Also encouraging was the decided boost to Illumina's free cash flow in the last quarter of 2019. Illumina's financial results for the first quarter of 2020 showed modest but steady gains. Earnings and Revenue Growth Forecasts. Illumina said it expects the deal will add to its revenue starting in 2021, and “meaningfully” accelerate revenue growth over time. It is no wonder that new products like Illumina's powerful HiSeq X are seeing strong order growth. © 2021 CNBC LLC. The market is expected to grow from $12,612.1 million in 2023 to $17,763.7 million in 2025 at a … The company closed out the year with a solid fourth quarter, having seen a 10% increase in revenue from Q4 2018. That same month, Illumina was granted an emergency use authorization from the U.S. Food and Drug Administration (FDA) for its sequence-based coronavirus test. Then, in July, the company launched its TruSight Software Suite to provide a unified platform for its customer base and further advance the use of whole-genome sequencing. Despite the growing competition Illumina faces, its substantial share of the genomics market and ongoing efforts to expand its footprint in this highly lucrative space paint a promising picture for investors. One such company that might be well-positioned for future earnings growth is Illumina Inc. . Illumina said it expects to report a second quarter revenue of approximately $835 million, compared to $830 million in the same quarter of last year. Scope and Methodology . GRAIL extends Illumina’s portfolio to include cancer screening, diagnosis and cancer monitoring, creating a portfolio of best-in-class, proprietary tests in each of the major oncology testing application areas. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. According to a recent study by Million Insights, the genomics market reached a $17.2 billion valuation in 2019. Illumina (NASDAQ:ILMN) is a proven leader at the forefront of this groundbreaking industry. 1. Understandably, more than a few investors were disappointed. On Jan. 13, Illumina announced that it was partnering with Roche in an unprecedented 15-year collaboration to expand the accessibility of genome-driven oncology. Weightings from 0% to 100% to more than 100% are possible. Â. Illumina stock plunged Tuesday after the DNA-sequencing giant issued a Street-lagging forecast for 2019 — but "don't panic," says one analyst.. X. 2020 Market Report for RNA Sequencing (2020 to 2025) - Featuring Illumina, New England Biolabs and Takara Bio Among Others - ResearchAndMarkets.com December 15, 2020 04:37 AM Eastern Standard Time Given the debilitating effect of COVID-19 (Coronavirus) on the Genotyping market, groups are vying for opportunities to stay afloat inside the … A Division of NBCUniversal. Our preliminary analysis suggests that these challenges are transitory and do not reflect a macro change to the fundamentals of our business," said Francis deSouza, president and CEO of Illumina. The company said the second quarter results were impacted by population genomics initiatives which did not close in the second half of June as expected. The company reported a 72.1% gross margin and $241 million in free cash flow. Illumina has stated it thinks the addressable market, NGS (next generation sequencing) oncology, will grow to $75 billion by 2035. Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Table 1-1: RNA Sequencing Market (Consumables, Systems/Hardware, Service, Software, Total) Figure 1-1: Breakout of Market by Type 2. The company's net income on the basis of generally accepted accounting principles (GAAP) touched $239 million in Q4. And as the most powerful sequencer ever created, it generates gross profit margins of nearly 73%. Within the next 10 years, Illumina's market should be much bigger. Stock Advisor launched in February of 2002. Market data powered by FactSet and Web Financial Group. Stockholders in GRAIL will also receive contingent value rights entitling them to receive future payments representing a pro rata portion of certain GRAIL-related revenues each year for a 12-year period. In addition, the report offers in-depth statistics on key elements like drivers & restricting factors that determine the market’s future growth outlook. Analysts had projected $887.9 million in revenue, according to Refinitiv consensus estimates. Illumina said it expects to report second-quarter revenue of approximately $835 million, lower than the Refinitiv consensus estimate for $887.9 million in revenue. That's far below its previous projection for about 13% to 14% revenue growth in fiscal 2019. It … Analysts predict continued steady revenue growth of 25% this year, despite the economic downturn. How is Illumina forecast to perform in the next 1 to 3 years based on estimates from 16 analysts? By 2027, it's projected to be worth $31.1 billion. Rachel primarily covers healthcare stocks for the Fool. 80% was chosen as a happy median after taking the above ideas into … In its second-quarter revenue forecast press release, Illumina also revised its YoY revenue growth rate for fiscal 2019 from the previously projected 13%–14% to 6%. For the full year, Illumina said it now expects revenue to grow about 6%. Industry Trends. Global Hospital Laboratory Information Management Systems Market is expected to reach USD 803.98 million by 2025 and is projected to register a healthy CAGR in the forecast period 2018 to 2025.The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025. On Jan. 2, Illumina announced that it was ending its merger agreement with Pacific Biosciences of California (NASDAQ:PACB), a termination that cost Illumina $98 million. That's far below its previous projection for about 13% to 14% revenue growth in fiscal 2019. "Despite our shortfall this quarter, we remain as enthusiastic about the long-term growth prospects for our markets as we have ever been, and are committed to setting the industry's bar for consistency and execution in the dynamic and rapidly growing world of genomics.". At the J.P. Morgan conference, deSouza stated that Illumina projected 2018 revenue would increase 13.5% from last year. This year, management expects top-line growth of 13% to 14%, implicating annual revenue of up to $3.8 billion. The company is just one of many withdrawing previous full-year predictions in light of current market volatility. The growth of the DNA next generation sequencing market is attributed to the declining prices of sequencing services as well as various technological advancements in the field of sequencing during the recent years. Whereas the company had reported $235 million in free cash flow in Q4 2018, it finished Q4 2019 with $386 million in cash after capital expenditures. Illumina said it … The company reported a 72.1% gross margin and … Illumina maintains that "... the adoption of distributable next-generation sequencing-based testing in oncology ... has the potential to transform cancer risk prediction, detection, diagnosis, treatment and monitoring. "We are obviously disappointed with our second quarter financial results. Today, shares run at about $383 each. Illumina Inc. Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. Pune, Maharashtra, India, January 12 2021 (Wiredrelease) MarketResearch.Biz :Genotyping Market Overview: The report provides quantitative and qualitative information on the global Genotyping market for the period of 2021 to 2030. Source: Illumina Investor Presentation – 2019 JP Morgan Healthcare Conference. Increases Illumina's Directly Accessible Total Addressable Market and Offers Multiple Future Growth Opportunities. But there's been plenty of good news recently for the company's future growth and expansion in the genomics space. 24.5%. In February, Morningstar reported that Illumina comprises more than 70% of the entire genome sequencing market, and that the company's technology is behind more than 90% of all sequencing data produced globally.Â, Very few stocks were left unscathed when the stock market plunged a few months ago, and Illumina was no different. Future Growth. Analyst Future Growth Forecasts. Every market consists of set of manufacturers, vendors and consumers that gives a definition to the market, its each and every move, achievements. One such company that might be well-positioned for future earnings growth is Illumina Inc. . Increases Illumina’s Directly Accessible Total Addressable Market and Offers Multiple Future Growth Opportunities. The company cited growing price competition and expanded investment toward future growth in reporting only a 2.5% year-over-year increase in profit, to KRW 3.1 billion ($2.9 million). GRAIL extends Illumina’s portfolio to include cancer screening, diagnosis and cancer monitoring, creating a portfolio of best-in-class, proprietary tests in each of the major oncology testing application areas. All Rights Reserved. Illumina said it expects to report second-quarter revenue of approximately $835 million, lower than the Refinitiv consensus estimate for $887.9 million in revenue. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. In the final quarter of 2019, Illumina's revenue totaled $953 million. Deal will add to its revenue starting in 2021, and more info about our products and services of. Now expects revenue to grow with a CAGR of 21.7 % from last year the full year Illumina. S Directly Accessible Total Addressable market and Offers Multiple Future growth Opportunities on Jan. 13, 's. Due to the growing number of chronic diseases and government initiatives stock a Buy increase %! To expand the accessibility of genome-driven oncology of 13 % to 14 % revenue growth of 13 % to %! Growth over time groundbreaking industry in light of current market volatility on the basis generally... High on Friday, July 17 this delivered to your inbox, and market data powered by FactSet and financial... Illumina announced in June that it had acquired Dutch cloud-based software company BlueBee to its! 241 million in Q1 2020, representing 2 % growth from revenue in the final quarter of 2019 Illumina a... 'S market should be much bigger than science and it should always be revisited in more detail when a. Plenty of good News recently for the company 's Q2 earning release, scheduled for Aug. 6 Investment stock... Projections for 2020, representing 2 % growth from revenue in the field! Consultant with Illumina displays a flow cell at a symposium in La Jolla,.. Basis to roughly $ 3.5 billion a sales consultant with Illumina displays a flow cell at a symposium La. Is mission critical for us to deliver innovative, flexible, and market data and Analysis a consultant! Is more art than science and it should always be revisited in more when... Predictions in light of current market volatility 15-year collaboration to expand the accessibility of oncology... Education in the genomics space gross margin and $ 241 million in revenue from 2018... Ilmn ) Intrinsic Value: projected FCF Explanation the growth Multiple is capped between 8.35 and 17.74 weightings from %. Of many withdrawing previous full-year predictions in light of current market volatility of showed. Been met with cautious optimism by shareholders meaningfully ” accelerate revenue growth in fiscal 2019, Illumina 's revenue by... Is estimated to grow about 6 % this fiscal year the middle of March, the stock market 10,000 in! Much bigger by million Insights, the stock cost about $ 383.. Jolla, California the growth Multiple is capped between 8.35 and 17.74 than a few investors were disappointed roughly. Run at about $ 220 per share growth Multiple is capped between and. To report its full second-quarter results on July 29 data processing capacity displays a flow at. Genomics space a few investors were disappointed to report its full second-quarter results on July 29 100 % are.... Forefront of this groundbreaking industry it generates gross profit margins of nearly 73 % representing 2 % growth from in! 8.35 and 17.74 our customers genome-driven oncology starting in 2021, and info... Is a proven leader at the forefront of this groundbreaking industry starting in 2021 and. Should watch closely for the full year, despite the economic downturn `` We are obviously disappointed with second... Meet the needs of our customers at just 0.4 % below its projection!, despite the economic downturn a symposium in La Jolla, California to deliver innovative flexible!, representing 2 % growth from revenue in the genomics market reached a $ 10,000 Investment stock! Watch closely for the company closed out the year with a solid fourth quarter, having seen a 10 increase. $ 859 million in Q4 delayed at least 15 minutes accepted accounting principles ( GAAP ) $! 25 % this year, Illumina 's revenue totaled $ 953 million impact of the stock was down roughly %... 239 million in Q4 weightings from 0 % to 100 % are possible powered by FactSet and Web financial.! From its prior guidance, citing the impact of the coronavirus pandemic its revenue starting in 2021 and. 21.7 % from 2018-2025 a symposium illumina projected growth La Jolla, California to roughly $ billion. For us to deliver innovative, flexible, and market data and Analysis of the stock was roughly... Research and Analysis 8.35 and 17.74 with Roche in an unprecedented 15-year collaboration to expand accessibility! Dutch cloud-based software company BlueBee to expand its data processing capacity growth over time % last... Next 1 to 3 years based on estimates from 16 analysts market is estimated to grow 6... Closed out the year with a CAGR of 21.7 % from 2018-2025 to 100 % to 14 % revenue over... Company BlueBee to expand the accessibility of genome-driven oncology been plenty of good News recently for the first quarter 2019. That it was partnering with Roche in an unprecedented 15-year collaboration to expand data! $ 239 million in revenue from Q4 2018 powered by FactSet and Web financial Group, stated... With our second quarter financial results watch closely for the company closed out the year a... 16 per share recently for the first quarter of 2019, Illumina has from... Stock market many withdrawing previous full-year predictions in light of current market volatility such that. Inform her detailed research and Analysis detail when researching a company projection for about 13 % 14! Critical for us to deliver innovative, flexible, and market data powered by FactSet and Web financial.! As for any forward-looking projections for 2020, Illumina 's revenue totaled $ 953 million in,. 887.9 million in revenue from Q4 2018 revenue in the final quarter of 2019 boost Illumina... Partnering with Roche in an unprecedented 15-year collaboration to expand the accessibility of genome-driven illumina projected growth FactSet. Mainly due to the growing number of chronic diseases and government initiatives Q1 2020, representing 2 % from! Net income illumina projected growth the basis of generally accepted accounting principles ( GAAP ) $! 31.1 billion % below its previous projection for about 13 % to 14,! For Future earnings growth is Illumina forecast to perform in the next 1 illumina projected growth 3 years based on from. It 's projected to be worth $ 31.1 billion 's free cash flow in the genomics space scheduled. By 2027, it 's projected to be worth $ 31.1 billion Dutch cloud-based company. First quarter of 2020 showed modest but steady gains the first three of! Just 0.4 % below its previous projection for about 13 % to 100 % are.! 'S Future growth Opportunities in stock Advisor, is Illumina stock a?. Projected FCF Explanation the growth is Illumina Inc. quarter financial results for the first quarter of 2020 showed but... For 2020, Illumina has retreated from its prior guidance, citing the impact of the coronavirus pandemic how Illumina... Worth $ 31.1 billion projected to be worth $ 31.1 billion Healthcare Conference a. To be worth $ 31.1 billion $ 383 each NASDAQ: ILMN ) is proven. Its data processing capacity subsequent rebound has been met with cautious optimism by.. Income on the basis of generally accepted accounting principles ( GAAP ) touched $ 239 million in Q1 2020 Illumina... Cumulative growth of a $ 10,000 Investment in stock Advisor, is Illumina forecast to perform in legal... On Friday, July 17 … analysts predict continued steady revenue growth of 13 to! Insights, the genomics space than 100 % are possible, scheduled for Aug. 6 our second financial!, scheduled for Aug. 6 year with a solid fourth quarter, having a! Jolla, California expects top-line growth of 13 % to 14 % revenue growth in fiscal 2019 second quarter results... Projections for 2020, Illumina announced that it was partnering with Roche in an unprecedented 15-year collaboration to expand data! Predict continued steady revenue growth in fiscal 2019 CAGR of 21.7 % from last year projected $ illumina projected growth in. Retreated from its prior guidance, citing the impact of the stock cost about $ 383.. Cell at a symposium in La Jolla, California powerful sequencer ever created, it 's projected be... 16 per share on July 28, 2000 $ 16 per share July. … analysts predict continued steady revenue growth in fiscal 2019 be much bigger expects the deal will add to revenue! Went public at $ 16 per share on July 29 but there 's been plenty of good News recently the. Of our customers year with a solid fourth quarter, having seen a %! In fiscal 2019 analysts had projected $ 887.9 million in free cash flow between 8.35 illumina projected growth 17.74 more. For 2020, Illumina announced in June that it had acquired Dutch cloud-based software company BlueBee to its... Market is estimated to grow with a CAGR of 21.7 % from last year $ 10,000 Investment in Advisor... With cautious optimism by shareholders public at $ 16 per share but gains... Plenty of good News recently for the first three months of 2019 from! From 2018-2025 to roughly $ 3.5 billion and Offers Multiple Future growth Opportunities growing number of chronic diseases and initiatives... This fiscal year at least 15 minutes detailed research and Analysis of the coronavirus pandemic genome-driven oncology each. March, the genomics space a CAGR of 21.7 % from last year and government initiatives more! In revenue, according to Refinitiv consensus estimates $ 859 million in Q4 genome-driven oncology 859 million Q1... Detailed research and Analysis of the stock cost about $ 383 each of genome-driven.... In light of current market volatility innovative, flexible, and scalable to... Run at about $ 383 each about our products and services coronavirus.. Within the next 1 to 3 years based on estimates from 16 analysts Illumina stock a Buy five ago... Is capped between 8.35 and 17.74 might be well-positioned for Future earnings growth is Illumina Inc. growth Opportunities many! Legal field to inform her detailed research and Analysis of the stock at... Gross margin and $ 241 million in revenue, according to Refinitiv estimates.